Traws Pharma Announced Topline Phase 1 Results For Its Covid Candidate, Ratutrelvir, An Oral Inhibitor Of The Main Protease
Portfolio Pulse from Benzinga Newsdesk
Traws Pharma announced positive Phase 1 results for its COVID-19 candidate, Ratutrelvir, an oral inhibitor. The drug was well-tolerated and achieved consistent plasma levels without ritonavir. Phase 2a study is expected in H1 2025.
September 30, 2024 | 11:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Traws Pharma's Ratutrelvir, a COVID-19 treatment, showed positive Phase 1 results, being well-tolerated and effective without ritonavir. Phase 2a trials are planned for H1 2025.
The positive Phase 1 results for Ratutrelvir indicate potential for successful further trials, which could enhance Traws Pharma's market position and stock value. The absence of ritonavir co-administration simplifies treatment, potentially increasing adoption.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100